Lilly to buy cancer drug developer AurKa Pharma for up to $575 millionStaff Writer | May 15, 2018
Eli Lilly and Company will buy AurKa Pharma in a deal potentially worth up to $575 million.
Acquisition AurKa Pharma will receive $110 million upfront
AurKa’s chief drug under development was discovered by Lilly, but the drugmaker sold the compound in 2016 to TVM Capital Life Science, which established AurKa.
The drug, AK-01, is being studied in early-stage trials to treat multiple types of solid tumors. ■